Abstract
The potential of 18Fluoro-deoxyglucose (FDG) positron emission tomography (PET) for the treatment of multiple myeloma has recently been evaluated. FDG-PET is a powerful imaging tool for the detection of bone lesions at initial diagnosis with high sensitivity and specificity values. The presence of extra-medullary lesions affects the prognosis. During therapeutic evaluation, FDG-PET is the reference imaging technique, because it can be performed much earlier than an MRI which lacks specificity. The negativity of FDG-PET before and after autologous stem cell transplantation is an independent favorable prognostic factor, especially for patients with a complete biological response.
In patients with smoldering multiple myeloma, the presence of one or more hyper-metabolic lytic lesions on FDG-PET may be considered as a criterion for initiating therapy. In the event of a suspect solitary plasmacytoma, the completion of a PET-FDG is indicated so as to not disregard other bone or extra-medullary localizations. The challenge of future multi-center prospective studies will be to standardize the interpretation criteria of FDG-PET, especially in the therapeutic evaluation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538–48.
Dimopoulos M, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the Management of Patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–64.
Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–66.
Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18(4):e206–17.
Dammacco F, Rubini G, Ferrari C, et al. 18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15(1):1–18.
Weng W-W, Dong M-J, Zhang J, et al. A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease-which is best? Asian Pac J Cancer Prev. 2014;15(22):9879–84.
Lu YY, Chen JH, Lin WY, et al. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med. 2012;37(9):833–7.
Walker RC, Brown TL, Jones-Jackson LB, et al. Imaging of multiple myeloma and related plasma cell dyscrasias. J Nucl Med. 2012;53(7):1091–101.
Sager S, Ergul N, Ciftci H, et al. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Skelet Radiol. 2011;40(7):843–7.
Mesguich C, Fardanesh R, Tanenbaum L, et al. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83(12):2203–23.
Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130(1):30–4.
Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–8.
Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712–9.
Van Lammeren-Venema D, Regelink JC, Riphagen II, et al. 8F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118(8):1971–81.
Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.
Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195–200.
Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De LS, Pane F, Salvatore M, Del VS. 18F-fdg pet/ct, 99mtc-mibi, and mri in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med. 2015;40(4):303–8.
Salaun P-Y, Gastinne T, Frampas E, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008;93(8):1269–71.
Fouquet G, Guidez S, Herbaux C, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254–60.
Siontis B, Kumar S, Dispenzieri A, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood. 2015;5:e364. https://doi.org/10.1038/bcj.2015.87.
Zamagni E, Nanni C, Gay F, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417–22.
Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76.
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. [Erratum appears in Blood. 2012 Sep 13;120(11):2349]. Blood. 2011;118(23):5989–95.
Haznedar R, Aki SZ, Akdemir OU, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046–53.
Park S, Lee SJ, Chang WJ, et al. Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. Acta Haematol. 2014;131(4):193–9.
Fonti R, Larobina M, Del Vecchio S, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829–35.
McDonald JE, Kessler MM, Gardner MW, et al. Assessment of Total lesion glycolysis by 18F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23(8):1981–7.
Carlier T, Bailly C, Leforestier R, et al. Prognostic added value of PET textural features at diagnosis in symptomatic multiple myeloma. Oral Communication SNM 2017.
Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23.
Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384–90.
Bailly C, Carlier T, Jamet B, et al. Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study. Clin Cancer Res. 2018.
Nanni C, Zamagni E, Celli M, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38(2):e74–9.
Derlin T, Weber C, Habermann CR, et al. 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39(3):493–500.
Lapa C, Lückerath K, Malzahn U, et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381–91.
Jamet B, Bailly C, Carlier T, et al. Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. Leuk Lymphoma. 2018:1–4.
Acknowledgments
“This work has been supported in part by grants from the French National Agency for Research called “Investissements d’Avenir” IRON Labex n° ANR-11-LABX-0018-01 and ArronaxPlus Equipex n° ANR-11-EQPX-0004, and by a grant INCa-DGOS-Inserm_12558 (SIRIC ILIAD).”
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jamet, B. et al. (2019). FDG PET in Multiple Myeloma. In: Nanni, C., Fanti, S., Zanoni, L. (eds) Molecular Imaging in Multiple Myeloma. Springer, Cham. https://doi.org/10.1007/978-3-030-19019-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-19019-4_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19018-7
Online ISBN: 978-3-030-19019-4
eBook Packages: MedicineMedicine (R0)